Limited data isn’t an issue when it comes to how to best use computational tools to better prevent disease and treat patients—but how to more efficiently analyze existing information is.

Industry veterans with experience in life sciences and data science floated their ideas about how the pharmaceutical industry could better plug in to the “big data” ecosystem during a BIO-Europe Spring panel last month. The annual conference, put on by EBD Group (which is owned by the same parent company as Xconomy), was held virtually last month given coronavirus concerns.

Industry and governments looking to tap into the potential of data… Read more »

Reprints | Share:   Retweet  Facebook  LinkedIn  Google Plus  E-mail